Treatment of experimental sepsis-induced immunoparalysis with TNF

被引:26
作者
Echtenacher, B
Urbaschek, R
Weigl, K
Freudenberg, MA
Männel, DN
机构
[1] Univ Regensburg, Inst Pathol Tumor Immunol, D-93042 Regensburg, Germany
[2] Heidelberg Univ, Inst Med Microbiol & Hyg, D-6800 Mannheim, Germany
[3] Max Planck Inst Immunobiol, Freiburg, Germany
关键词
TUMOR-NECROSIS-FACTOR; MICE; IL-10; LIPOPOLYSACCHARIDE; INTERLEUKIN-10; REQUIREMENT; DEFICIENT; ENDOTOXIN; SHOCK;
D O I
10.1078/0171-2985-00282
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Following a severe septic abdominal infection induced by sublethal cecal ligation and puncture (CLP) in mice, a phase of depressed immune reactivity occurred two days after CLP characterized by a reduced capacity to produce TNF. To determine whether this reduced TNF production causes immunoparalysis as determined by increased susceptibility to bacterial infection and whether therapeutic TNF substitution can be beneficial during this phase, a super-infection with Salmonella enterica Serovar typhimurium or Listeria monocytogenes was induced two days after sublethal CLP. After CLP a state of true immunoparalysis developed during which Salmonella or Listeria super-infection led to increased lethality paralleled by increased bacterial numbers in spleens and livers. Injection of recombinant human TNF before or at the time of super-infection conferred protection to Salmonella but not to Listeria. In the latter case, the infection mortality was even enhanced. Thus, super-infection during the state of sepsis-induced immunoparalysis leads to increased lethality. TNF substitution during this state of immunoparalysis can be beneficial or deleterious, depending on the location of TNF activity in the animal, timing of TNF administration, or the type of super-infection. These results demonstrate that impaired TNF production capacity can account for some aspects of immunoparalysis, however, diagnostic parameters are required for a safe TNF substitution therapy.
引用
收藏
页码:381 / 389
页数:9
相关论文
共 24 条
[1]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[2]   Intrapulmonary TNF gene therapy reverses sepsis-induced suppression of lung antibacterial host defense [J].
Chen, GH ;
Reddy, RC ;
Newstead, MW ;
Tateda, K ;
Kyasapura, BL ;
Standiford, TJ .
JOURNAL OF IMMUNOLOGY, 2000, 165 (11) :6496-6503
[3]   Critical protective role of mast cells in a model of acute septic peritonitis [J].
Echtenacher, B ;
Mannel, DN ;
Hultner, L .
NATURE, 1996, 381 (6577) :75-77
[4]  
ECHTENACHER B, 1990, J IMMUNOL, V145, P3762
[5]   Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice [J].
Echtenacher, B ;
Weigl, K ;
Lehn, N ;
Männel, DN .
INFECTION AND IMMUNITY, 2001, 69 (06) :3550-3555
[6]  
GALANOS C, 1979, ZBL BAKT-INT J MED M, V243, P226
[7]  
HAVELL EA, 1989, J IMMUNOL, V143, P2894
[8]   The essential role of lipopolysaccharide-binding protein in protection of mice against a peritoneal Salmonella infection involves the rapid induction of an inflammatory response [J].
Heinrich, JM ;
Bernheiden, M ;
Minigo, G ;
Yang, KK ;
Schütt, C ;
Männel, DN ;
Jack, RS .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1624-1628
[9]   Immunomodulatory therapies in sepsis [J].
Kox, WJ ;
Volk, T ;
Kox, SN ;
Volk, HD .
INTENSIVE CARE MEDICINE, 2000, 26 (Suppl 1) :S124-S128
[10]   Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome - A new approach: Proof of principle [J].
Kox, WJ ;
Bone, RC ;
Krausch, D ;
Docke, WD ;
Kox, SN ;
Wauer, H ;
Egerer, K ;
Querner, S ;
Asadullah, K ;
vonBaehr, R ;
Volk, HD .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (04) :389-393